These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
27. The fading star of obinutuzumab-chlorambucil regimen in patients with comorbidities with chronic lymphocytic leukemia - are we ready for chemo-free immunotherapy approach? Milunović V; Mišura Jakobac K; Mandac Rogulj I; Martinović M; Radić-Krišto D; Ostojić Kolonić S Expert Rev Hematol; 2020 Jul; 13(7):771-779. PubMed ID: 32579408 [TBL] [Abstract][Full Text] [Related]
28. Acalabrutinib, venetoclax, and obinutuzumab as frontline treatment for chronic lymphocytic leukaemia: a single-arm, open-label, phase 2 study. Davids MS; Lampson BL; Tyekucheva S; Wang Z; Lowney JC; Pazienza S; Montegaard J; Patterson V; Weinstock M; Crombie JL; Ng SY; Kim AI; Jacobson CA; LaCasce AS; Armand P; Arnason JE; Fisher DC; Brown JR Lancet Oncol; 2021 Oct; 22(10):1391-1402. PubMed ID: 34534514 [TBL] [Abstract][Full Text] [Related]
29. Ibrutinib, idelalisib and obinutuzumab for the treatment of patients with chronic lymphocytic leukemia: three new arrows aiming at the target. Morabito F; Gentile M; Seymour JF; Polliack A Leuk Lymphoma; 2015; 56(12):3250-6. PubMed ID: 26062943 [TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States. Chatterjee A; Shapouri S; Manzoor BS; Ravelo A; Sail K; Qendri V; van de Wetering G; Davids MS J Manag Care Spec Pharm; 2021 Nov; 27(11):1532-1544. PubMed ID: 34714110 [No Abstract] [Full Text] [Related]
32. Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves. Alrawashdh N; Persky DO; McBride A; Sweasy J; Erstad B; Abraham I Clin Lymphoma Myeloma Leuk; 2021 Nov; 21(11):e820-e831. PubMed ID: 34274291 [TBL] [Abstract][Full Text] [Related]
33. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. Maddocks KJ; Ruppert AS; Lozanski G; Heerema NA; Zhao W; Abruzzo L; Lozanski A; Davis M; Gordon A; Smith LL; Mantel R; Jones JA; Flynn JM; Jaglowski SM; Andritsos LA; Awan F; Blum KA; Grever MR; Johnson AJ; Byrd JC; Woyach JA JAMA Oncol; 2015 Apr; 1(1):80-7. PubMed ID: 26182309 [TBL] [Abstract][Full Text] [Related]
34. Fixed Duration of Venetoclax-Rituximab in Relapsed/Refractory Chronic Lymphocytic Leukemia Eradicates Minimal Residual Disease and Prolongs Survival: Post-Treatment Follow-Up of the MURANO Phase III Study. Kater AP; Seymour JF; Hillmen P; Eichhorst B; Langerak AW; Owen C; Verdugo M; Wu J; Punnoose EA; Jiang Y; Wang J; Boyer M; Humphrey K; Mobasher M; Kipps TJ J Clin Oncol; 2019 Feb; 37(4):269-277. PubMed ID: 30523712 [TBL] [Abstract][Full Text] [Related]
35. Minimal residual disease in chronic lymphocytic leukaemia. García Vela JA; García Marco JA Med Clin (Barc); 2018 Feb; 150(4):144-149. PubMed ID: 28864095 [TBL] [Abstract][Full Text] [Related]
36. Ibrutinib combinations in CLL therapy: scientific rationale and clinical results. Timofeeva N; Gandhi V Blood Cancer J; 2021 Apr; 11(4):79. PubMed ID: 33927183 [TBL] [Abstract][Full Text] [Related]
37. Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia. Blair HA Drugs; 2020 Dec; 80(18):1973-1980. PubMed ID: 33201424 [TBL] [Abstract][Full Text] [Related]
38. Indirect Treatment Comparisons of Ibrutinib Versus Physician's Choice and Idelalisib Plus Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia. Sorensen S; Wildgust M; Sengupta N; Trambitas C; Diels J; van Sanden S; Xu Y; Dorman E Clin Ther; 2017 Jan; 39(1):178-189.e5. PubMed ID: 28062113 [TBL] [Abstract][Full Text] [Related]
39. Efficacy of bendamustine and rituximab in unfit patients with previously untreated chronic lymphocytic leukemia. Indirect comparison with ibrutinib in a real-world setting. A GIMEMA-ERIC and US study. Cuneo A; Mato AR; Rigolin GM; Piciocchi A; Gentile M; Laurenti L; Allan JN; Pagel JM; Brander DM; Hill BT; Winter A; Lamanna N; Tam CS; Jacobs R; Lansigan F; Barr PM; Shadman M; Skarbnik AP; Pu JJ; Sehgal AR; Schuster SJ; Shah NN; Ujjani CS; Roeker L; Orlandi EM; Billio A; Trentin L; Spacek M; Marchetti M; Tedeschi A; Ilariucci F; Gaidano G; Doubek M; Farina L; Molica S; Di Raimondo F; Coscia M; Mauro FR; de la Serna J; Medina Perez A; Ferrarini I; Cimino G; Cavallari M; Cucci R; Vignetti M; Foà R; Ghia P; Cancer Med; 2020 Nov; 9(22):8468-8479. PubMed ID: 32969597 [TBL] [Abstract][Full Text] [Related]
40. Phase II Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Treatment-Naïve and Relapsed or Refractory Chronic Lymphocytic Leukemia. Rogers KA; Huang Y; Ruppert AS; Abruzzo LV; Andersen BL; Awan FT; Bhat SA; Dean A; Lucas M; Banks C; Grantier C; Heerema NA; Lozanski G; Maddocks KJ; Valentine TR; Weiss DM; Jones JA; Woyach JA; Byrd JC J Clin Oncol; 2020 Nov; 38(31):3626-3637. PubMed ID: 32795224 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]